
Sallie Anne Pearson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1023089/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effect of Salt Substitution on Cardiovascular Events and Death. New England Journal of Medicine, 2021, 385, 1067-1077.	13.9	321
2	Interrupted time series analysis using autoregressive integrated moving average (ARIMA) models: a guide for evaluating large-scale health interventions. BMC Medical Research Methodology, 2021, 21, 58.	1.4	252
3	Computerized clinical decision support for prescribing: provision does not guarantee uptake. Journal of the American Medical Informatics Association: JAMIA, 2010, 17, 25-33.	2.2	235
4	The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers. BMC Research Notes, 2015, 8, 634.	0.6	220
5	An overview of the patterns of prescription opioid use, costs and related harms in <scp>A</scp> ustralia. British Journal of Clinical Pharmacology, 2014, 78, 1159-1166.	1.1	172
6	Do computerised clinical decision support systems for prescribing change practice? A systematic review of the literature (1990-2007). BMC Health Services Research, 2009, 9, 154.	0.9	163
7	Twentyâ€five years of prescription opioid use in Australia: a wholeâ€ofâ€population analysis using pharmaceutical claims. British Journal of Clinical Pharmacology, 2016, 82, 255-267.	1.1	142
8	Retrospective studies of end-of-life resource utilization and costs in cancer care using health administrative data: A systematic review. Palliative Medicine, 2014, 28, 1167-1196.	1.3	135
9	Interventions designed to improve the quality and efficiency of medication use in managed care: A critical review of the literature – 2001–2007. BMC Health Services Research, 2008, 8, 75.	0.9	113
10	Polypharmacy among older Australians, 2006–2017: a populationâ€based study. Medical Journal of Australia, 2019, 211, 71-75.	0.8	111
11	Finding solutions to the rural doctor shortage: the roles of selection versus undergraduate medical education at Newcastle. Australian and New Zealand Journal of Medicine, 1995, 25, 512-517.	0.5	105
12	Health care use and costs at the end of life: a comparison of elderly Australian decedents with and without a cancer history. BMC Palliative Care, 2018, 17, 1.	0.8	98
13	Inappropriate prescribing of preventative medication in patients with life-limiting illness: a systematic review. BMJ Supportive and Palliative Care, 2017, 7, 113-121.	0.8	94
14	Do junior doctors feel they are prepared for hospital practice? A study of graduates from traditional and non-traditional medical schools. Medical Education, 1998, 32, 19-24.	1.1	90
15	Older peoples' attitudes regarding polypharmacy, statin use and willingness to have statins deprescribed in Australia. International Journal of Clinical Pharmacy, 2015, 37, 949-957.	1.0	86
16	Rising pregabalin use and misuse in Australia: trends in utilization and intentional poisonings. Addiction, 2019, 114, 1026-1034.	1.7	75
17	Low-value care in Australian public hospitals: prevalence and trends over time. BMJ Quality and Safety, 2019, 28, 205-214.	1.8	57
18	Measuring Hospital-Acquired Complications Associated With Low-Value Care. JAMA Internal Medicine, 2019, 179, 499.	2.6	57

#	Article	IF	CITATIONS
19	The crux of the matter: Did the ABC's Catalyst program change statin use in Australia?. Medical Journal of Australia, 2015, 202, 591-594.	0.8	53
20	A systematic review and metaâ€analysis of prescribing practices of antidepressants in cancer patients. Psycho-Oncology, 2016, 25, 1002-1016.	1.0	51
21	Psychotropic medication use in Australia, 2007 to 2015: Changes in annual incidence, prevalence and treatment exposure. Australian and New Zealand Journal of Psychiatry, 2017, 51, 990-999.	1.3	51
22	Codeine use and harms in Australia: evaluating the effects of reâ€scheduling. Addiction, 2020, 115, 451-459.	1.7	47
23	Trastuzumab and Metastatic Breast Cancer: Trastuzumab Use in Australia—Monitoring the Effect of an Expensive Medicine Access Program. Journal of Clinical Oncology, 2007, 25, 3688-3693.	0.8	46
24	Trends in self-poisoning and psychotropic drug use in people aged 5–19 years: a population-based retrospective cohort study in Australia. BMJ Open, 2019, 9, e026001.	0.8	45
25	Factors affecting progress of Australian and international students in a problem-based learning medical course. Medical Education, 2000, 34, 708-715.	1.1	43
26	What proportion of patients with chronic noncancer pain are prescribed an opioid medicine? Systematic review and metaâ€regression of observational studies. Journal of Internal Medicine, 2020, 287, 458-474.	2.7	42
27	Decision making in CPR: attitudes of hospital patients and healthcare professionals. Medical Journal of Australia, 1998, 169, 128-131.	0.8	38
28	Factors influencing prescribing: an intern's perspective. Medical Education, 2002, 36, 781-787.	1.1	38
29	Developing indicators for measuring low-value care: mapping Choosing Wisely recommendations to hospital data. BMC Research Notes, 2018, 11, 163.	0.6	37
30	Changes in antibiotic prescribing following COVIDâ€19 restrictions: Lessons for postâ€pandemic antibiotic stewardship. British Journal of Clinical Pharmacology, 2022, 88, 1143-1151.	1.1	37
31	Trends in opioid utilisation in Australia, 2006â€2015: Insights from multiple metrics. Pharmacoepidemiology and Drug Safety, 2018, 27, 504-512.	0.9	36
32	To what extent do data from pharmaceutical claims underâ€estimate opioid analgesic utilisation in Australia?. Pharmacoepidemiology and Drug Safety, 2018, 27, 550-555.	0.9	35
33	National trends in alcohol pharmacotherapy: Findings from an Australian claims database. Drug and Alcohol Dependence, 2016, 166, 254-257.	1.6	34
34	Studies using Australia's Pharmaceutical Benefits Scheme data for pharmacoepidemiological research: a systematic review of the published literature (1987-2013). Pharmacoepidemiology and Drug Safety, 2015, 24, 447-455.	0.9	33
35	High risk prescribing in older adults: prevalence, clinical and economic implications and potential for intervention at the population level. BMC Public Health, 2013, 13, 115.	1.2	32
36	Interrupted Time Series Analysis of the Effect of Rescheduling Alprazolam in Australia. JAMA Internal Medicine, 2016, 176, 1223.	2.6	31

#	Article	IF	CITATIONS
37	Communication skills of interns in New South Wales. Medical Journal of Australia, 1994, 161, 667-670.	0.8	30
38	Long-term use of proton-pump inhibitors: whole-of-population patterns in Australia 2013–2016. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482091374.	1.4	30
39	Racial Disparities in Access After Regulatory Surveillance of Benzodiazepines. Archives of Internal Medicine, 2006, 166, 572.	4.3	29
40	Evaluating medicines: let's use all the evidence. Medical Journal of Australia, 2007, 186, 249-252.	0.8	29
41	Quantifying low-value care: a patient-centric versus service-centric lens. BMJ Quality and Safety, 2017, 26, 855-858.	1.8	28
42	Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study. British Journal of Clinical Pharmacology, 2017, 83, 2581-2588.	1.1	28
43	Availability, Formulation, Labeling, and Price of Low-sodium Salt Worldwide: Environmental Scan. JMIR Public Health and Surveillance, 2021, 7, e27423.	1.2	28
44	Impact of written information on knowledge and preferences for cardiopulmonary resuscitation. Medical Journal of Australia, 1999, 171, 239-242.	0.8	27
45	Prevalence of statin-drug interactions in older people: a systematic review. European Journal of Clinical Pharmacology, 2016, 72, 513-521.	0.8	27
46	Prevalence of Potential and Clinically Relevant Statin–Drug Interactions in Frail and Robust Older Inpatients. Drugs and Aging, 2015, 32, 849-856.	1.3	25
47	Electronic information and clinical decision support for prescribing: state of play in Australian general practice. Family Practice, 2011, 28, 93-101.	0.8	24
48	Changes in sales of analgesics to pharmacies after codeine was rescheduled as a prescription only medicine. Medical Journal of Australia, 2020, 212, 321-327.	0.8	24
49	Ascertainment of self-reported prescription medication use compared with pharmaceutical claims data. Public Health Research and Practice, 2017, 27, .	0.7	24
50	Uncovering the potential risk of serotonin toxicity in Australian veterans using pharmaceutical claims data. British Journal of Clinical Pharmacology, 2008, 66, 682-688.	1.1	23
51	Trastuzumab for metastatic breast cancer: Real world outcomes from an Australian whole-of-population cohort (2001–2016). Breast, 2018, 38, 7-13.	0.9	23
52	Risk of squamous cell carcinoma of the lip and cutaneous melanoma in older Australians using hydrochlorothiazide: A populationâ€based caseâ€control study. Basic and Clinical Pharmacology and Toxicology, 2020, 127, 320-328.	1.2	23
53	Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique. European Journal of Health Economics, 2014, 15, 93-112.	1.4	21
54	Measuring 21 low-value hospital procedures: claims analysis of Australian private health insurance data (2010–2014). BMJ Open, 2019, 9, e024142.	0.8	21

#	Article	IF	CITATIONS
55	Trastuzumab therapy in Australia: Which patients with HER2+ metastatic breast cancer are assessed for cardiac function?. Breast, 2013, 22, 482-487.	0.9	20
56	A methodological protocol for selecting and quantifying low-value prescribing practices in routinely collected data: an Australian case study. Implementation Science, 2017, 12, 58.	2.5	20
57	Attitudes towards community medicine: a comparison of students from traditional and community-oriented medical schools. Medical Education, 1999, 33, 606-611.	1.1	19
58	Validation and application of a death proxy in adult cancer patients. Pharmacoepidemiology and Drug Safety, 2012, 21, 742-748.	0.9	19
59	Antidepressant therapy in cancer patients: initiation and factors associated with treatment. Pharmacoepidemiology and Drug Safety, 2015, 24, 600-609.	0.9	19
60	Changing medication use in managed care: a critical review of the available evidence. American Journal of Managed Care, 2003, 9, 715-31.	0.8	19
61	Information sources used by New South Wales cancer clinicians: a qualitative study. Internal Medicine Journal, 2006, 36, 711-717.	0.5	18
62	Positive spillover effects of prescribing requirements: increased cardiac testing in patients treated with trastuzumab for <scp>HER2+</scp> metastatic breast cancer. Internal Medicine Journal, 2012, 42, 1229-1235.	0.5	18
63	Initiation of strong prescription opioids in Australia: cohort characteristics and factors associated with the type of opioid initiated. British Journal of Clinical Pharmacology, 2016, 82, 1123-1133.	1.1	18
64	A national study on prescribed medicine use in Australia on a typical day. Pharmacoepidemiology and Drug Safety, 2020, 29, 1046-1053.	0.9	18
65	Changes in antidepressant use in Australia: A nationwide analysis (2015–2021). Australian and New Zealand Journal of Psychiatry, 2023, 57, 49-57.	1.3	18
66	Implementing a webâ€based oncology protocol system in Australia: evaluation of the first 3 years of operation. Internal Medicine Journal, 2012, 42, 57-64.	0.5	17
67	Combating escalating harms associated with pharmaceutical opioid use in Australia: the POPPY II study protocol. BMJ Open, 2018, 8, e025840.	0.8	17
68	Patterns of immediate breast reconstruction in New South Wales, Australia: a populationâ€based study. ANZ Journal of Surgery, 2019, 89, 1230-1235.	0.3	17
69	Metastatic breast cancer incidence, site and survival in Australia, 2001–2016: a population-based health record linkage study protocol. BMJ Open, 2019, 9, e026414.	0.8	17
70	The role of comorbidities on the uptake of systemic treatment and 3-year survival in older cancer patients. Annals of Oncology, 2012, 23, 2422-2428.	0.6	16
71	Standardizing care in medical oncology. Cancer, 2009, 115, 5579-5588.	2.0	15
72	Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort. BMJ Open, 2017, 7, e014439.	0.8	15

#	Article	IF	CITATIONS
73	An audit of cancer of unknown primary notifications: A cautionary tale for population health research using cancer registry data. Cancer Epidemiology, 2014, 38, 460-464.	0.8	14
74	Health service utilisation and investigations before diagnosis of cancer of unknown primary (CUP): A population-based nested case–control study in Australian Government Department of Veterans' Affairs clients. Cancer Epidemiology, 2015, 39, 585-592.	0.8	14
75	Longâ€ŧerm trajectories of medicine use among older adults experiencing polypharmacy in Australia. British Journal of Clinical Pharmacology, 2021, 87, 1264-1274.	1.1	14
76	A comparison of practice outcomes of graduates from traditional and non-traditional medical schools in Australia. Medical Education, 2002, 36, 985-991.	1.1	13
77	Patterns of analgesic and anti-inflammatory medicine use by Australian veterans. Internal Medicine Journal, 2007, 37, 798-805.	0.5	13
78	The quality of web-based oncology guidelines and protocols: how do international sites stack up?. British Journal of Cancer, 2011, 105, 1166-1172.	2.9	13
79	Real-World Evidence: A Comparison of the Australian Herceptin Program and Clinical Trials of Trastuzumab for HER2-Positive Metastatic Breast Cancer. Pharmacoeconomics, 2016, 34, 1039-1050.	1.7	13
80	Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006–2014). British Journal of Cancer, 2018, 118, 441-447.	2.9	13
81	Current Opioid Access, Use, and Problems in Australasian Jurisdictions. Current Addiction Reports, 2018, 5, 464-472.	1.6	12
82	Exploring variation in low-value care: a multilevel modelling study. BMC Health Services Research, 2019, 19, 345.	0.9	12
83	Passing the acid test? Evaluating the impact of national education initiatives to reduce proton pump inhibitor use in Australia. BMJ Quality and Safety, 2020, 29, 365-373.	1.8	12
84	A cross sectional study of psychotropic medicine use in Australia in 2018: A focus on polypharmacy. British Journal of Clinical Pharmacology, 2021, 87, 1369-1377.	1.1	12
85	Diagnosis-based and external cause-based criteria to identify adverse drug reactions in hospital ICD-coded data: application to an Australia population-based study. Public Health Research and Practice, 2017, 27, .	0.7	12
86	Intern Prescribing Decisions: Few and Far Between. Education for Health: Change in Learning and Practice, 2002, 15, 315-325.	0.1	11
87	eviQ cancer treatments online: How does the webâ€based protocol system fare in a comprehensive quality assessment?. Asia-Pacific Journal of Clinical Oncology, 2011, 7, 357-363.	0.7	11
88	The use and impact of cancer medicines in routine clinical care: methods and observations in a cohort of elderly Australians. BMJ Open, 2014, 4, e004099.	0.8	11
89	Patterns of care and survival after a cancer of unknown primary (CUP) diagnosis: A population-based nested cohort study in Australian Government Department of Veterans' Affairs clients. Cancer Epidemiology, 2015, 39, 578-584.	0.8	11
90	Anticholinergic medicines use among older adults before and after initiating dementia medicines. British Journal of Clinical Pharmacology, 2019, 85, 1957-1963.	1.1	11

#	Article	IF	CITATIONS
91	Health-related quality of life among HIV-infected patients initiating treatment in Brazil in the single-tablet regimen era. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2019, 31, 572-581.	0.6	11
92	The Prevalence of Opioid Analgesic Use in People with Chronic Noncancer Pain: Systematic Review and Meta-Analysis of Observational Studies. Pain Medicine, 2021, 22, 506-517.	0.9	11
93	Changes in systemic cancer therapy in Australia during the COVID-19 pandemic: a population-based study. The Lancet Regional Health - Western Pacific, 2021, 14, 100226.	1.3	11
94	Generating Real-World Evidence on the Quality Use, Benefits and Safety of Medicines in Australia: History, Challenges and a Roadmap for the Future. International Journal of Environmental Research and Public Health, 2021, 18, 13345.	1.2	11
95	Validation of a proxy for estrogen receptor status in breast cancer patients using dispensing data. Asia-Pacific Journal of Clinical Oncology, 2014, 10, e63-8.	0.7	10
96	Resource use, costs and quality of end-of-life care: observations in a cohort of elderly Australian cancer decedents. Implementation Science, 2015, 10, 25.	2.5	10
97	Choosing wisely? Quantifying the extent of three low value psychotropic prescribing practices in Australia. BMC Health Services Research, 2018, 18, 1009.	0.9	10
98	Screening recommendations in general practice: a survey of graduates from different medical schools. Medical Journal of Australia, 1996, 165, 14-17.	0.8	9
99	Accidental pharmacological poisonings in young children: population-based study in three settings. Clinical Toxicology, 2018, 56, 782-789.	0.8	9
100	Person-level changes in oxycodone use after the introduction of a tamper-resistant formulation in Australia. Cmaj, 2018, 190, E355-E362.	0.9	9
101	Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007–2016). British Journal of Cancer, 2019, 121, 904-911.	2.9	9
102	Prescription opioid dispensing in Australian children and adolescents: a national population-based study. The Lancet Child and Adolescent Health, 2019, 3, 881-888.	2.7	9
103	Patterns of pregabalin initiation and discontinuation after its subsidy in Australia. British Journal of Clinical Pharmacology, 2020, 86, 1882-1887.	1.1	9
104	A population-based study of transdermal fentanyl initiation in Australian clinical practice. European Journal of Clinical Pharmacology, 2019, 75, 401-408.	0.8	8
105	Potentially inappropriate benzodiazepine use in Australian adults: A populationâ€based study (2014–2017). Drug and Alcohol Review, 2020, 39, 575-582.	1.1	8
106	Adherence to Antiretroviral Regimens in Australia: A Nationwide Cohort Study. AIDS Patient Care and STDs, 2020, 34, 81-91.	1.1	8
107	The relationship between assessment measures at Newcastle Medical School (Australia) and performance ratings during internship. Medical Education, 1998, 32, 40-45.	1.1	7
108	The impact of permissive and restrictive pharmaceutical policies on quetiapine dispensing: Evaluating a policy pendulum using interrupted time series analysis. Pharmacoepidemiology and Drug Safety, 2018, 27, 439-446.	0.9	7

#	Article	IF	CITATIONS
109	Trastuzumab use in older patients with HER2-positive metastatic breast cancer: outcomes and treatment patterns in a whole-of-population Australian cohort (2003–2015). BMC Cancer, 2019, 19, 909.	1.1	7
110	Barriers and Facilitators to Implementing Reduced-Sodium Salts as a Population-Level Intervention: A Qualitative Study. Nutrients, 2021, 13, 3225.	1.7	7
111	Prescription Opioid Access Patterns and Factors Associated with Increasing Number of Prescribers, Pharmacies, and Dispensings: An Observational Study Using Pharmaceutical Claims. Pain Medicine, 2018, 19, 1170-1183.	0.9	6
112	Increases in controlledâ€release oxycodone utilisation following the subsidy of oxycodone with naloxone formulations: An Australian populationâ€based study. Pharmacoepidemiology and Drug Safety, 2019, 28, 97-105.	0.9	6
113	Evidenceâ€practice gaps in <scp>P2Y₁₂</scp> inhibitor use after hospitalisation for acute myocardial infarction: findings from a new populationâ€level data linkage in Australia. Internal Medicine Journal, 2022, 52, 249-258.	0.5	6
114	Australian Suicide Prevention using Health-Linked Data (ASHLi): Protocol for a population-based case series study. BMJ Open, 2020, 10, e038181.	0.8	6
115	The changing face of Australian data reforms: Impact on pharmacoepidemiology research. International Journal of Population Data Science, 2021, 6, 1418.	0.1	6
116	Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort. Breast, 2021, 58, 106-112.	0.9	6
117	Comparison of long-term outcomes of bioprosthetic and mechanical aortic valve replacement in patients under 65 years. Journal of Thoracic and Cardiovascular Surgery, 2022, , .	0.4	6
118	Prescribed medicine use and extent of offâ€label use according to age in a nationwide sample of Australian children. Paediatric and Perinatal Epidemiology, 2022, 36, 726-737.	0.8	6
119	Uptake of a web-based oncology protocol system: how do cancer clinicians use eviQ cancer treatments online?. BMC Cancer, 2013, 13, 112.	1.1	5
120	Looking forward and looking back: the balancing act in new drug user designs for pharmacoepidemiological research. Pharmacoepidemiology and Drug Safety, 2015, 24, 1117-1119.	0.9	5
121	Improving the Legitimacy of Medicines Funding Decisions: A Critical Literature Review. Therapeutic Innovation and Regulatory Science, 2015, 49, 364-368.	0.8	5
122	Validating a proxy for disease progression in metastatic cancer patients using prescribing and dispensing data. Asia-Pacific Journal of Clinical Oncology, 2017, 13, e246-e252.	0.7	5
123	Variations in Longâ€ŧerm Opioid Therapy Definitions: A Systematic Review of Observational Studies Using Routinely Collected Data (2000â€2019). British Journal of Clinical Pharmacology, 2021, 87, 3706-3720.	1.1	5
124	Changes in dispensing of medicines proposed for re-purposing in the first year of the COVID-19 pandemic in Australia. PLoS ONE, 2022, 17, e0269482.	1.1	5
125	How do medical doctors use a web-based oncology protocol system? A comparison of Australian doctors at different levels of medical training using logfile analysis and an online survey. BMC Medical Informatics and Decision Making, 2013, 13, 82.	1.5	4
126	How well do NSW hospital data identify cases of heart failure?. Medical Journal of Australia, 2014, 200, 25-25.	0.8	4

#	Article	lF	CITATIONS
127	Adherence to prescribing restrictions for HER2-positive metastatic breast cancer in Australia: A national population-based observational study (2001-2016). PLoS ONE, 2018, 13, e0198152.	1.1	4
128	Consumer perspectives of accelerated access to medicines: a qualitative study. Journal of Health Organization and Management, 2021, 35, 987-1007.	0.6	4
129	Resource stratified guidelines for cancer: Are they all the same? Interguideline concordance for systemic treatment recommendations. International Journal of Cancer, 2022, 150, 91-99.	2.3	4
130	Insights from linking routinely collected data across Australian health jurisdictions: a case study of end-of-life health service use. Public Health Research and Practice, 2018, 28, .	0.7	4
131	Trends in transdermal fentanyl utilisation and fatal fentanyl overdose across Australia (2003–2015). Drug and Alcohol Review, 2021, , .	1.1	4
132	Age-stratified outcomes of bioprosthetic and mechanical aortic valve replacements in an Australian cohort of 13 377 patients. BMJ Surgery, Interventions, and Health Technologies, 2020, 2, e000036.	0.6	4
133	Rates of Low-Value Service in Australian Public Hospitals and the Association With Patient Insurance Status. JAMA Network Open, 2021, 4, e2138543.	2.8	4
134	A scale to measure attitudes toward community medicine. Australian and New Zealand Journal of Public Health, 1996, 20, 433-435.	0.8	3
135	Chemotherapy Administration. Pharmacoeconomics, 2012, 30, 1173-1186.	1.7	3
136	Are NCCN Resource-Stratified Guidelines for Breast Cancer Systemic Therapy Achievable? A Population-Based Study of Global Need and Economic Impact. JCO Global Oncology, 2021, 7, 1074-1083.	0.8	3
137	Retrospective comparison of Australia's Pharmaceutical Benefits Scheme claims data with prescription data in HER2-positive early breast cancer patients, 2008–2012. Public Health Research and Practice, 2017, 27, .	0.7	3
138	Nitrogen-based Bisphosphonate Use and Ovarian Cancer Risk in Women Aged 50 Years and Older. Journal of the National Cancer Institute, 2022, 114, 878-884.	3.0	3
139	Antihypertensive polytherapy in Australia: prevalence of inappropriate combinations, 2013–2018. Journal of Hypertension, 2020, 38, 1586-1592.	0.3	2
140	Hospital characteristics associated with low-value care in public hospitals in New South Wales, Australia. BMC Health Services Research, 2020, 20, 750.	0.9	2
141	Patterns of oxycodone controlled release use in older people with cancer following public subsidy of oxycodone/naloxone formulations: An Australian populationâ€based study. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 68-78.	0.7	2
142	Cardiac assessment in Australian patients receiving (neo)adjuvant trastuzumab for HER2-positive early breast cancer: a population-based study. Breast Cancer Research and Treatment, 2021, 187, 893-902.	1.1	2
143	Trajectories of pregabalin use and their association with longitudinal changes in opioid and benzodiazepine use. Pain, 2022, 163, e614-e621.	2.0	2
144	Hydroxyzine Initiation Following Drug Safety Advisories on Cardiac Arrhythmias in the UK and Canada: A Longitudinal Cohort Study. Drug Safety, 2022, , 1.	1.4	2

#	Article	IF	CITATIONS
145	Improving the quality of oncology guidelines and protocols. Asia-Pacific Journal of Clinical Oncology, 2012, 8, 313-313.	0.7	1
146	Optimizing the Impact of Drugs on Symptom Burden in Older People With Multimorbidity at the End of Life. JAMA Internal Medicine, 2014, 174, 636.	2.6	1
147	Benchmarking prescription drug access patterns in pharmaceutical claims: a method for identifying high and potentially harmful opioid use in Australia and Canada?. Journal of Pharmaceutical Health Services Research, 2017, 8, 23-30.	0.3	1
148	Response to: â€~Sentinel lymph node biopsy for in situ melanoma is unlikely in Australia' by Morton and Thompson. BMJ Quality and Safety, 2019, 28, 255-256.	1.8	1
149	Dispensing Practices of Fixed Dose Combination Controller Therapy for Asthma in Australian Children and Adolescents. International Journal of Environmental Research and Public Health, 2020, 17, 5645.	1.2	1
150	Estimating misclassification error in a binary performance indicator: case study of low value care in Australian hospitals. BMJ Quality and Safety, 2020, 29, 992-999.	1.8	1
151	Coming to grips with seemingly conflicting results in programme evaluation: the devil's in the detail. BMJ Quality and Safety, 2021, 30, 70-71.	1.8	1
152	Prescription opioid use in Australian women of reproductive age: implications for unplanned pregnancies. British Journal of Clinical Pharmacology, 2021, , .	1.1	1
153	Manual versus automated coding of free-text self-reported medication data in the 45 and Up Study: a validation study. Public Health Research and Practice, 2015, 25, e2521518.	0.7	1
154	Identifying incident cancer cases in dispensing claims. International Journal of Population Data Science, 2020, 5, 1152.	0.1	1
155	Incidence and risk factors of hypertension therapy in Australian cancer patients treated with vascular signalling pathway inhibitors. Discover Oncology, 2022, 13, 6.	0.8	1
156	Parity in female authorship in Australian pharmacoepidemiology research leveraging medicine dispensing data: How well are we doing?. Pharmacoepidemiology and Drug Safety, 2022, 31, 1010-1012.	0.9	1
157	Trends in HIV post-exposure prophylaxis following sexual exposure in Brazil (2011–2019). AIDS and Behavior, 0, , .	1.4	1
158	Use of Trastuzumab for Metastatic Breast Cancer in Australia: Interpreting Findings From a Cohort of 1,469 Women on a National Access Program Versus 41 Women Treated by Two Medical Oncologists. Journal of Clinical Oncology, 2007, 25, 5663-5664.	0.8	0
159	Author reply. Internal Medicine Journal, 2013, 43, 611-611.	0.5	0
160	Too much or not enough? A comment on discrepancies in published estimates of opioid use in Australia. Internal Medicine Journal, 2016, 46, 1230-1231.	0.5	0
161	Exercise trials for blood pressure control: keeping it REAL. British Journal of Sports Medicine, 2019, 53, 1443-1444.	3.1	0
162	Anticipating the effects of restricting highâ€dose preparations of strong opioids in Australia: A populationâ€based analysis to inform the current policy debate. Pharmacoepidemiology and Drug Safety, 2019, 28, 521-527.	0.9	0

#	Article	IF	CITATIONS
163	Patterns of opioid use in older people diagnosed with cancer in New South Wales, Australia. Pharmacoepidemiology and Drug Safety, 2021, 30, 360-370.	0.9	0
164	The Australian Pharmaceutical Benefits Scheme (PBS) Dispensing Database. Springer Series on Epidemiology and Public Health, 2021, , 255-266.	0.5	0
165	Realâ€world data to advance HER2â€ŧargeted cancer medicines research: Playing to the strengths of clinical registry and administrative data. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 414-415.	0.7	0
166	288What proportion of patients with chronic noncancer pain are prescribed an opioid medicine?. International Journal of Epidemiology, 2021, 50, .	0.9	0
167	A sorry tale of unnecessary secrecy about medicine safety. Internal Medicine Journal, 2021, 51, 1765-1766.	0.5	0
168	Comparison of claims from high–drug cost beneficiaries in Ontario, Canada, and Australia: a cross-sectional analysis. CMAJ Open, 2021, 9, E1048-E1054.	1.1	0
169	Prioritising access to cancer drugs. Lancet Oncology, The, 2022, 23, e1.	5.1	0
170	Assessing the impact of implementing multiple adherence measures to antiretroviral therapy from dispensing data: a short report. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2022, , 1-6.	0.6	0
171	The impact of tightened prescribing restrictions on proton pump inhibitor use in Australia: An evaluation using interrupted time series analysis. Pharmacoepidemiology and Drug Safety, 2022, 31, 370-378.	0.9	0
172	OUP accepted manuscript. Journal of the National Cancer Institute, 2022, , .	3.0	0
173	Post-Discharge Antithrombotic Therapy Following Transcatheter Aortic Valve Implantation in Australian Patients. Heart Lung and Circulation, 2022, , .	0.2	Ο